• News

"Elotuzumab Plus Stem Cell Transplant Shows Promise For Multiple Myeloma" — Alexandra Todak

  • Healio
  • New York, NY
  • (February 22, 2018)

The addition of elotuzumab and autologous peripheral blood mononuclear cell reconstitution to autologous hematopoietic stem cell transplantation plus lenalidomide maintenance appeared effective with a manageable safety profile, according to results of a phase 1b open‐label trial presented at BMT Tandem Meetings. “The autologous HSCT platform is a good setting for exploring immunotherapeutic therapies, because it is a platform in which there is minimal disease burden and immunogenic cell death,” said Keren Osman, MD, associate professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, during her presentation. She concluded that, “These results suggest elotuzumab and lenalidomide may support persistence or increases in clonal T‐cell populations posttransplant.”She added that a phase two study is planned.

  • Keren Osman, MD, Associate Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai

Learn more

Additonal coverage:
Hematology Times